IMPEDIMED LIMITED — Board/Management Information 2009

Nov 10, 2009

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text ----- ASX : IPD----- End of picture text -----

11th November 2009

ASX RELEASE

IMPEDIMED APPOINTS CHIEF FINANCIAL OFFICER

ImpediMed CEO Greg Brown today announced the appointment of Mr Donald Myll as the company’s CFO. Mr Myll will be located at the company’s San Diego facility in the United States, and his appointment completes the building of a senior executive team. Mr Brown said the CFO role was obviously an important one for ImpediMed, and with Don’s extensive commercial and financial experience, his appointment is likely to have an immediate positive impact in spearheading our push into the US and global markets.

Mr Myll has an impressive track record in the commercial sector. Of particular note was his involvement in TheraTx as the co-founder and CFO. TheraTx (NASDAQ: THTX), was a highly successful, publicly traded diversified healthcare company providing rehabilitation, post-acute care, long term care and occupational health services. He was responsible for all the financial and corporate support aspects of the business as the company grew from inception to over $400 million in revenue and 8,000 employees in 7 years. Mr Myll’s other notable experience includes having been the Senior VP of Operations and CFO for Ambit Biosciences Corp., CFO at AMN Healthcare Services Inc. as well as Daou Systems Inc. Mr Myll commenced his career as an Audit and Senior Tax Associate at Arthur Andersen & Co. Mr Myll has been directly involved in raising over USD$1 billion in capital raisings in the U.S throughout his career.

Mr Myll said that his background with successful rapid-growth health care services companies and this appointment provides him with the opportunity to use his skill sets, network contacts and experience to be a part of a team driving ImpediMed to a leadership position in the medical device market.

“It seems to me the work ImpediMed is doing, not only positions itself as a market leader in assisting medical providers in the prevention of lymphedema, but more importantly potentially protects the quality of life of cancer patients post surgery,” Mr Myll said.

Mr Brown said the appointment of Mr Myll to the leadership team completes ImpediMed’s commitment to build a highly experienced senior executive team to manage the roll out of the Company’s global launch.

For further information contact:

Greg Brown ImpediMed CEO +61-7-3860-3700

1/2

L-Dex[®] is a trademark of ImpediMed Limited.

“ L-Dex[® ] values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity”.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.